Accellix raises $10M from BroadOak Capital Partners

By The Science Advisory Board staff writers

December 13, 2021 -- Accellix has raised $10 million from BroadOak Capital Partners. Accellix is a biotechnology company that provides flow cytometry results in a compact, easy-to-use platform for use by cell therapy companies on the manufacturing floor and at the point of need.

BroadOak provides flexible growth capital and mergers and acquisitions advice for companies in the life sciences industry that provide tools and services. The investment is part of BroadOak's fifth fund and marks the firm's third investment in the last six months in the rapidly growing market of tools and services for cell and gene therapy development and manufacturing. BroadOak previously invested in Accellix as part of a prior fund.

Promising cell therapies continue to progress to the late stages of clinical development and into commercial products, increasing the need for routine and streamlined quality control (QC) process management. Accellix's products streamline a complex but necessary part of cell analysis, providing more robust outcomes and reducing overall QC costs in cell therapy manufacturing.

Filling a gap so biotech startups can advance to the next level
In the biotechnology industry, there is a need for capital among companies that are already commercial and have products with demonstrated success but...

Copyright © 2021

Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
International Society for Pharmaceutical Engineering Annual Meeting
October 30 - November 2
Orlando, Florida United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter